International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines.

  title={International collaboration to assess the risk of Guillain Barr{\'e} Syndrome following Influenza A (H1N1) 2009 monovalent vaccines.},
  author={Caitlin N Dodd and Silvana Antonietta Romio and Steven V Black and Claudia J Vellozzi and Nick Andrews and Miriam C. J. M. Sturkenboom and Patrick Zuber and Wei Hua and Jan Bonhoeffer and Jim P. Buttery and Nigel P. S. Crawford and Genevi{\`e}ve Deceuninck and Corinne S. de Vries and P De Wals and M Victoria Guti{\'e}rrez-Gimeno and Harald Heijbel and Hayley Hughes and K. B. Hur and A Hviid and Jeffrey Kelman and Tehri Kilpi and Shuk Kwan Chuang and Kristine Macartney and Melisa D. Rett and Vesta Richardson Lopez-Callada and Daniel Salmon and Francisco Gim{\'e}nez-S{\'a}nchez and Nuria Sanz and Barbara Silverman and Jann Storsaeter and Umapathi Thirugnanam and Nicoline A T van der Maas and Katherine W Yih and Tao Zhang and H{\'e}ctor Izurieta},
  volume={31 40},
BACKGROUND The global spread of the 2009 novel pandemic influenza A (H1N1) virus led to the accelerated production and distribution of monovalent 2009 Influenza A (H1N1) vaccines (pH1N1). This pandemic provided the opportunity to evaluate the risk of Guillain-Barré syndrome (GBS), which has been an influenza vaccine safety concern since the swine flu pandemic of 1976, using a common protocol among high and middle-income countries. The primary objective of this project was to demonstrate the… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS